Endotoxinemia and benzodiazepine-like substances in compensated cirrhotic patients: A randomized study comparing the effect of rifaximine alone and in association with a symbiotic preparation

Hepatology Research

Volumn 28, Issue 3, 2004, Pages 155-160

  Lighthouse, J ^a   Naito, Y ^a   Helmy, A ^b   Hotten, P ^a   Fuji, H ^c   Min, C H ^a   Yoshioka, M ^a   Marotta, F ^a,d  

^a Noguchi Mem Research Ph Institute   (Japan)

^b MENOUFIA UNIVERSITY   (Egypt)

^c Osato Research Institute   (Japan)

^d NONE   (Italy)

Author keywords

Benzodiazepine like substances; Hepatic encephalopathy; Rifaximine; SCM III

Indexed keywords

AMMONIA; BENZODIAZEPINE DERIVATIVE; DISACCHARIDE; ENDOTOXIN; FUROSEMIDE; ION; LACTITOL; LACTULOSE; POTASSIUM SPARING DIURETIC AGENT; PROBIOTIC AGENT; RIFAXIMIN; URSODEOXYCHOLIC ACID; VITAMIN;

ARTICLE; BIFIDOBACTERIUM; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CULTURE MEDIUM; DIAGNOSTIC PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG USE; ENDOTOXEMIA; FEMALE; HEPATIC ENCEPHALOPATHY; HEPATITIS C VIRUS; HUMAN; INTERMETHOD COMPARISON; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS HELVETICUS; LIVER CIRRHOSIS; LONG TERM CARE; MALE; MONOTHERAPY; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYMBIOSIS; VIRUS INFECTION;

EID: 1242340455     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hepres.2003.11.005     Document Type: Article

References (31)

1. Avallone R. Corsi L. Zanoli P. Substances and benzodiazepine-like activity in food and vegetal compounds: physiological and pathological implications Acta Phytother. 3 1997 42-50 [in Italian]
2. Medina J.H. Paladini A.C. Izquierdo I. Naturally occurring benzodiazepines and benzodiazepine-like molecules in brain Behav. Brain Res. 20 1993 1-8
3. Yurdaydin C. Walsh T.J. Engler H.D. Ha J.H. Li Y. Jones E.A. et al. Gut bacteria provide precursors of benzodiazepine receptor ligands in a rat model of hepatic encephalopathy Brain Res. 679 1995 42-48
4. Unseld E. Klotz U. Benzodiazepines: are they of natural origin? Pharm. Res. 6 1989 1-3
5. Avallone R. Zeneroli M.L. Venturini I. Corsi L. Schreier P. Kleinschnitz M. et al. Endogenous benzodiazepine-like compounds and diazepam binding inhibitor in serum of patients with liver cirrhosis with and without overt encephalopathy Gut 42 1998 861-867
6. Mullen KD, Martin JV, Mendelson WB, Bassett ML, Jones EA. Could an endogenous benzodiazepine ligand contribute to hepatic encephalopathy? Lancet 1998;1(Feb (27)):457-9 (Review).
7. Zeneroli M.L. Venturini I. Avallone R. Farina F. Miglioli L. Cosenza R. et al. Changes in endogenous benzodiazepine-like compound levels during the course of fulminant hepatic failure: potential effects of decreased renal function Ital. J. Gastroenterol. Hepatol. 29 1997 456-458
8. Zeneroli M.L. Venturini I. Corsi L. Avallone R. Farina F. Ardizzone G. et al. Benzodiazepin-like compounds in the plasma of patients with fulminant hepatic failure Scand. J. Gastroenterol. 33 1998 310-313
9. Fenton J.C.B. Knoghts E.J. Humpherson P.L. Milk and cheese diet in portal-systemic encephalopathy Lancet 1 1966 164-166
10. Loguercio C. Abbiati R. Rinaldi M. Romano A. Blanco C.D.V. Coltorti M. Longterm effects of Enterococcus faeccum SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy J. Hepatol. 23 1995 39-46
11. Hotten P. Marotta F. Naito Y. Minelli E. Helmy A. Lighthouse J. et al. Effects of probiotics, lactitol and rifaximine on intestinal flora and fecal excretion of organic acics in cirrhotics Chin. J. Dig. Dis. 4 2003 13-18
12. Barreto R. Marotta F. Naito Y. Tajiri H. Safran P. Kato Y. et al. Enhancement of interferon production and phagocytic function in aged rats by an enriched probiotic mixture J. Food Sci. Nutr. Suppl. 3 1998 S31-S37
13. Marotta F, Naito Y, Minelli E, Tajiri H, Bertuccelli J, Wu CC. Chemopreventive effect of a probiotic preparation on the development of preneoplastic and neoplastic colonic lesions: an experimental study. Hepatogastroenterology, in press.
14. Zeneroli M.L. Venturini I. Stefanelli S. Farina F. Miglioli R.C. Minelli E. et al. Antibacterial activity of rifaximine reduces the levels of benzodiazepine-like compounds in patients with liver cirrhosis Pharmacol. Res. 356 1997 557-560
15. Gillis J.C. Brogden R.N. Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal flora Drugs 49 1995 467-484
16. Conn HO, Lieberthal MM. The hepatic coma syndrome and lactulose. Baltimore, MD: Williams & Wilkins; 1979.
17. Quero J.C. Hartmann I.J. Meulstee J. The diagnosis of subclinical hepatic encephalopathy in patients with cirrhosis using neuropsychological tests and automated electroencephalogram analysis Hepatology 24 1994 556-560
18. Conn H.O. Trailmaking and number connection tests in the assessment of mental state in portal systemic encephalopathy Am. J. Dig. Dis. 22 1977 541-550
19. Fukui H. Brauner B. Bode J.Ch. Bode Ch. Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: re-evaluation with an improved chromogenic assay J. Hepatol. 5 1991 162-169
20. Bode C. Fukui H. Bode J.Ch. "Hidden" endotoxin in plasma of patients with alcoholic liver disease Eur. J. Gastroenterol. Hepatol. 5 1993 247-262
21. Olasmaa M. Rothstein J.D. Guidotti A. Weber R.J. Paul S.M. Spector S. et al. Endogenous benzodiazepine receptor ligands in humans and animal hepatic encephalopathy J. Neurochem. 55 1990 2015-2023
22. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal. Biochem. 72 1976 248-254
23. Scollo-Lavizzari G. Steinmann E. Reversal of hepatic coma by benzodiazepine antagonist (Ro 15-1788) Lancet 1 1985-1324
24. Basile A.S. Harrison P.M. Hughes R.D. Gu Z.Q. Pannell L. McKinney A. Relationship between plasma benzodiazepine receptor ligand concentrations and severity of hepatic encephalopathy Hepatology 19 1994 112-121
25. Barbaro G. Di Lorenzo G. Soldini M. Giancaspro G. Bellomo G. Belloni G. Flumazenil for hepatic encephalopathy grades III and IVa in patients with cirrhosis: an Italian multicenter double-blind placebo-controlled cross-over study Hepatology 28 1998 374-378
26. Ferenci P. Grimm G. Meryn S. Gangl A. Successful long-term treatment of portal-systemic encephalopathy by the benzodiazepine antagonist flumazenil Gastroenterology 96 1998 240-243
27. Venturini I. Corsi L. Avallone R. Farina F. Bedogni G. Baraldi C. et al. Ammonia and endogenous benzodiazepine-like compounds in the pathogenesis of hepatic encephalopathy Scand J. Gastroenterol. 36 2001 423-425
28. Basile A.S. Jones E.A. Ammonia and GABAergic neurotransmission: interrelated factors in the pathogenesis of hepatic encephalopathy Hepatology 25 1997 1303-1305
29. Mullen K.D. Jones E.A. Natural benzodiazepines and hepatic encephalopathy Semin. Liver Dis. 16 1996 255-264
30. Effimiadi C. Deleo C. Schito G.C. Treatment of hepatic encephalopathy with L/105. A new non-absorbable ryfamicin Drug Exp. Clin. Res. 10 1984 691-696
31. Jalan R. Turjanski N. Taylor-Robinson S.D. Koep M.J. Richardson M.P. Wilson J.A. et al. Increased availability of central benzodiazepine receptors in patients with chronic hepatic encephalopathy and alcohol related cirrhosis Gut 46 2000 546-552